Skip to main content

Advertisement

Springer Nature Link
Log in

In vivo imaging of immunotoxin treatment using Katushka-transfected A-431 cells in a murine xenograft tumour model

  • Original article
  • Published:
Cancer Immunology, Immunotherapy Aims and scope Submit manuscript

Abstract

Purpose

Preclinical in vivo analyses of treatment responses are an important prerequisite to evaluate new therapeutics. Molecular in vivo imaging in the far red (FR)/near infra red (NIR) is a promising method, as it enables measurements at different time points in individual animals, thereby reducing the number of animals required, while increasing statistical significance. Here, we show the establishment of a method to monitor response to treatment using fluorescent cells, expressing the epidermal growth factor receptor (EGFR), a target already used in therapy.

Methods

We transfected A-431 tumour cells with the far red–emitting protein Katushka (Kat2), resulting in strong fluorescence allowing for the monitoring of tumour growth when implanted in BALB/c nu/nu mice with a CRi Maestro in vivo imager. We targeted A-431 cells with a previously reported immunotoxin (IT), consisting of the anti-EGFR antibody single-chain variable fragment (scFv) 425, fused to Pseudomonas aeruginosa Exotoxin A’ (ETA’). In addition, EGFR expression was verified using the 425(scFv) conjugated to a NIR dye BG-747 through a SNAP-tag linker.

Results

The results show the feasibility to evaluate response to treatment in vivo by FR imaging, while at the same location detecting EGFR expression. Treatment with 425(scFv)-ETA’ resulted in decelerated tumour growth, while not affecting the overall health of the animals. This is in contrast to treatment with Doxorubicin, which, although decreasing the tumour size, resulted in poor health.

Conclusions

We developed a novel method to non-invasively determine treatment responses by in vivo imaging of multiple parameters which showed the efficacy of 425(scFv)-ETA’.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price includes VAT (Canada)

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Contag PR (2002) Whole-animal cellular and molecular imaging to accelerate drug development. Drug Discov Today 7:555–562

    Article  PubMed  CAS  Google Scholar 

  2. Chalfie M, Tu Y, Euskirchen G, Ward WW, Prasher DC (1994) Green fluorescent protein as a marker for gene expression. Science 263:802–805

    Article  PubMed  CAS  Google Scholar 

  3. Alford R, Ogawa M, Choyke PL, Kobayashi H (2009) Molecular probes for the in vivo imaging of cancer. Mol Biosyst 5:1279–1291

    Article  PubMed  CAS  Google Scholar 

  4. Gong H, Kovar J, Little G, Chen H, Olive DM (2010) In vivo imaging of xenograft tumors using an epidermal growth factor receptor-specific affibody molecule labeled with a near-infrared fluorophore. Neoplasia 12:139–149

    PubMed  CAS  Google Scholar 

  5. Weissleder R (2001) A clearer vision for in vivo imaging. Progress continues in the development of smaller, more penetrable probes for biological imaging. Nat Biotechnol 19:316–317

    Article  PubMed  CAS  Google Scholar 

  6. Shcherbo D, Merzlyak EM, Chepurnykh TV, Fradkov AF, Ermakova GV, Solovieva EA et al (2007) Bright far-red fluorescent protein for whole-body imaging. Nat Methods 4:741–746

    Article  PubMed  CAS  Google Scholar 

  7. Haigler H, Ash JF, Singer SJ, Cohen S (1978) Visualization by fluorescence of the binding and internalization of epidermal growth factor in human carcinoma cells A-431. Proc Natl Acad Sci USA 75:3317–3321

    Article  PubMed  CAS  Google Scholar 

  8. Tolmachev V, Rosik D, Wållberg H, Sjöberg A, Sandström M, Hansson M et al (2010) Imaging of EGFR expression in murine xenografts using site-specifically labelled anti-EGFR 111In-DOTA-Z EGFR:2377 Affibody molecule: aspect of the injected tracer amount. Eur J Nucl Med Mol Imag 37:613–622

    Article  Google Scholar 

  9. Abdollahi A, Griggs DW, Zieher H, Roth A, Lipson KE, Saffrich R et al (2005) Inhibition of alpha(v)beta3 integrin survival signaling enhances antiangiogenic and antitumor effects of radiotherapy. Clin Cancer Res 11:6270–6279

    Article  PubMed  CAS  Google Scholar 

  10. Shao W, Zhao S, Liu Z, Zhang J, Ma S, Sato JD et al (2006) Inhibition of human tumor xenograft growth in nude mice by a conjugate of monoclonal antibody LA22 to epidermal growth factor receptor with anti-tumor antibiotics mitomycin C. Biochem Biophys Res Commun 349:816–824

    Article  PubMed  CAS  Google Scholar 

  11. Cohen MH, Williams GA, Sridhara R, Chen G, Pazdur R (2003) FDA drug approval summary: Gefitinib (ZD1839)(Iressa (R)) tablets. Oncologist 8:303–306

    Article  PubMed  CAS  Google Scholar 

  12. Cohen MH, Johnson JR, Chen YF, Sridhara R, Pazdur R (2005) FDA drug approval summary: erlotinib (Tarceva (R)) tablets. Oncologist 10:461–466

    Article  PubMed  CAS  Google Scholar 

  13. Vincenzi B, Zoccoli A, Pantano F, Venditti O, Galluzzo S (2010) Cetuximab: from bench to bedside. Curr Cancer Drug Targets 10:80–95

    Article  PubMed  CAS  Google Scholar 

  14. Giusti RM, Shastri KA, Cohen MH, Keegan P, Pazdur R (2007) FDA drug approval summary: panitumumab (Vectibix). Oncologist 12:577–583

    Article  PubMed  CAS  Google Scholar 

  15. Camp ER, Summy J, Bauer TW, Liu W, Gallick GE, Ellis LM (2005) Molecular mechanisms of resistance to therapies targeting the epidermal growth factor receptor. Clin Cancer Res 11:397–405

    PubMed  CAS  Google Scholar 

  16. Bruell D, Stöcker M, Huhn M, Redding N, Küpper M, Schumacher P et al (2003) The recombinant anti-EGF receptor immunotoxin 425(scFv)-ETA’ suppresses growth of a highly metastatic pancreatic carcinoma cell line. Int J Oncol 23:1179–1186

    PubMed  CAS  Google Scholar 

  17. Bruell D, Bruns CJ, Yezhelyev M, Huhn M, Müller J, Ischenko I et al (2005) Recombinant anti-EGFR immunotoxin 425 (scFv)-ETA’ demonstrates anti-tumor activity against disseminated human pancreatic cancer in nude mice. Int J Mol Med 15:305–313

    PubMed  CAS  Google Scholar 

  18. Barth S, Huhn M, Matthey B, Tawadros S, Schnell R, Schinköthe T et al (2000) Ki-4(scFv)-ETA’, a new recombinant anti-CD30 immunotoxin with highly specific cytotoxic activity against disseminated Hodgkin tumors in SCID mice. Blood 95:3909–3914

    PubMed  CAS  Google Scholar 

  19. Huhn M, Sasse S, Tur MK, Matthey B, Schinköthe T, Rybak SM, et al. (2001) Human angiogenin fused to human CD30 Ligand (Ang-CD30L) exhibits specific cytotoxicity against CD30-positive lymphoma. Cancer Res 61:8737–8742

    Google Scholar 

  20. Tur M, Huhn M, Thepen T, Stöcker M, Krohn R, Vogel S et al (2003) Recombinant CD64-specific single chain immunotoxin exhibits specific cytotoxicity against acute myeloid leukemia cells. Cancer Res 63:8414–8419

    PubMed  CAS  Google Scholar 

  21. Stahnke B, Thepen T, Stöcker M, Rosinke R, Jost E, Fischer R et al (2008) Granzyme B-H22(scFv), a human immunotoxin targeting CD64 in acute myeloid leukemia of monocytic subtypes. Mol Cancer Ther 7:2924–2932

    Article  PubMed  CAS  Google Scholar 

  22. Tur MK, Neef I, Jost E, Galm O, Jäger G, Stöcker M et al (2009) Targeted restoration of down-regulated DAPK2 tumor suppressor activity induces apoptosis in Hodgkin lymphoma cells. J Immunother 32:431–441

    Article  PubMed  CAS  Google Scholar 

  23. Pastan I, Hassan R, Fitzgerald DJ, Kreitman RJ (2006) Immunotoxin therapy of cancer. Nat Rev Cancer 6:559–565

    Article  PubMed  CAS  Google Scholar 

  24. Pastan I, Hassan R, FitzGerald DJ, Kreitman RJ (2007) Immunotoxin treatment of cancer. Annu Rev Med 58:221–237

    Article  PubMed  CAS  Google Scholar 

  25. Kreitman RJ, Wilson WH, Bergeron K, Raggio M, Stetler-Stevenson M, Fitzgerald DJ et al (2001) Efficacy of the anti-CD22 recombinant immunotoxin BL22 in chemotherapy-resistant hairy-cell leukemia. N Engl J Med 345:241–247

    Article  PubMed  CAS  Google Scholar 

  26. Wayne AS, Kreitman RJ, Findley HW, Lew G, Delbrook C, Steinberg SM et al (2010) Anti-CD22 immunotoxin RFB4(dsFv)-PE38 (BL22) for CD22-positive hematologic malignancies of childhood: preclinical studies and phase I clinical trial. Clin Cancer Res 16:1894–1903

    Article  PubMed  CAS  Google Scholar 

  27. Hanahan D, Weinberg RA (2000) The hallmarks of cancer. Cell 100:57–70

    Article  PubMed  CAS  Google Scholar 

  28. Luo J, Solimini NL, Elledge SJ (2009) Principles of cancer therapy: oncogene and non-oncogene addiction. Cell 136:823–837

    Article  PubMed  CAS  Google Scholar 

  29. Li C, Iida M, Dunn EF, Ghia AJ, Wheeler DL (2009) Nuclear EGFR contributes to acquired resistance to cetuximab. Oncogene 28:3801–3813

    Article  PubMed  CAS  Google Scholar 

  30. Arteaga CL (2003) EGF receptor as a therapeutic target: patient selection and mechanisms of resistance to receptor-targeted drugs. J Clin Oncol 21:289s–291s

    Article  PubMed  Google Scholar 

  31. Kampmeier F, Ribbert M, Nachreiner T, Dembski S, Beaufils F, Brecht A et al (2009) Site-specific, covalent labeling of recombinant antibody fragments via fusion to an engineered version of 6-O-alkylguanine DNA alkyltransferase. Bioconjug Chem 20:1010–1015

    Article  PubMed  CAS  Google Scholar 

  32. Kampmeier F, Niesen J, Koers A, Ribbert M, Brecht A, Fischer R et al (2010) Rapid optical imaging of EGF receptor expression with a single-chain antibody SNAP-tag fusion protein. Eur J Nucl Med Mol Imag 37:1926–1934

    Article  CAS  Google Scholar 

  33. Matthey B, Engert A, Klimka A, Diehl V, Barth S (1999) A new series of pET-derived vectors for high efficiency expression of Pseudomonas exotoxin-based fusion proteins. Gene 229:145–153

    Article  PubMed  CAS  Google Scholar 

  34. Ribbert T, Thepen T, Tur MK, Fischer R, Huhn M, Barth S (2010) Improved efficacy by increased valency, both in vitro, as well as in vivo in a chronic cutaneous inflammation model in hCD64 transgenic mice. Br J Dermatol 162:1–3

    Article  Google Scholar 

  35. Kapp U, Wolf J, Von Kalle C, Tawadros S, Röttgen A, Engert A et al (1992) Preliminary report: growth of Hodgkin’s lymphoma derived cells in immune compromised mice. Ann Oncol 3:S21–S23

    Google Scholar 

  36. Stocker M, Tur MK, Sasse S, Krüßmann A, Barth S, Engert A (2003) Secretion of functional anti-CD30-angiogenin immunotoxins into the supernatant of transfected 293T-cells. Protein Expr Purif 28:211–219

    Article  PubMed  CAS  Google Scholar 

  37. Johansen PB (1981) Doxorubicin pharmacokinetics after intravenous and intraperitoneal administration in the nude mouse. Cancer Chemother Pharmacol 5:267–270

    Article  PubMed  CAS  Google Scholar 

  38. Mizutani H, Tada-Oikawa S, Hiraku Y, Kojima M, Kawanishi S (2005) Mechanism of apoptosis induced by doxorubicin through the generation of hydrogen peroxide. Life Sci 76:1439–1453

    Article  PubMed  CAS  Google Scholar 

  39. Ajaj KA, Graeser R, Fichtner I, Kratz F (2009) In vitro and in vivo study of an albumin-binding prodrug of doxorubicin that is cleaved by cathepsin B. Cancer Chemother Pharmacol 64:413–418

    Article  PubMed  Google Scholar 

  40. Jensen MM, Jørgensen JT, Binderup T, Kjaer A (2008) Tumor volume in subcutaneous mouse xenografts measured by microCT is more accurate and reproducible than determined by 18F-FDG-microPET or external caliper. BMC Med Imag 8:16

    Article  Google Scholar 

  41. He X, Nie H, Wang K, Tan W, Wu X, Zhang P (2008) In vivo study of biodistribution and urinary excretion of surface-modified silica nanoparticles. Anal Chem 80:9597–9603

    Article  PubMed  CAS  Google Scholar 

  42. Kobayashi H, Longmire MR, Ogawa M, Choyke PL (2011) Rational chemical design of the next generation of molecular imaging probes based on physics and biology: mixing modalities, colors and signals. Chem Soc Rev 40:4626–4648

    Article  PubMed  CAS  Google Scholar 

  43. Barrett T, Koyama Y, Hama Y, Ravizzini G, Shin IS, Jang BS et al (2007) In vivo diagnosis of epidermal growth factor receptor expression using molecular imaging with a cocktail of optically labeled monoclonal antibodies. Clin Cancer Res 13:6639–6648

    Article  PubMed  CAS  Google Scholar 

  44. Urano Y, Asanuma D, Hama Y, Koyama Y, Barrett T, Kamiya M et al (2009) Selective molecular imaging of viable cancer cells with pH-activatable fluorescence probes. Nat Med 15:104–109

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgments

We thank Dirk Scheffler, Reinhard Rosinke and Peggy Jirak for excellent technical assistance. This publication is based upon work that was in part financed by the Bundesministerium für Bildung und Forschung (0315254A/B). The responsibility for the content of this publication lies with the author.

Conflict of interest

The authors declare that they have no conflict of interest.

Author information

Authors and Affiliations

  1. Department of Experimental Medicine and Immunotherapy, Institute for Applied Medical Engineering, Helmholtz Institute of RWTH Aachen University & Hospital, Pauwelsstraße 20, 52074, Aachen, Germany

    Alessa Pardo, Michael Stöcker, Florian Kampmeier & Stefan Barth

  2. PharmedArtis GmbH, Forckenbeckstraße 6, 52074, Aachen, Germany

    Georg Melmer

  3. Department of Pharmaceutical Product Development, Fraunhofer IME, Forckenbeckstraße 6, 52074, Aachen, Germany

    Rainer Fischer, Theo Thepen & Stefan Barth

Authors
  1. Alessa Pardo
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Michael Stöcker
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Florian Kampmeier
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Georg Melmer
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Rainer Fischer
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Theo Thepen
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Stefan Barth
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Theo Thepen.

Additional information

Theo Thepen and Stefan Barth contributed equally to the paper.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Supplementary material 1 (PDF 6643 kb)

Rights and permissions

Reprints and permissions

About this article

Cite this article

Pardo, A., Stöcker, M., Kampmeier, F. et al. In vivo imaging of immunotoxin treatment using Katushka-transfected A-431 cells in a murine xenograft tumour model. Cancer Immunol Immunother 61, 1617–1626 (2012). https://doi.org/10.1007/s00262-012-1219-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00262-012-1219-3

Keywords

Search

Navigation